Dextroamphetamine Sulfate

Quick links to important sections

Dextroamphetamine Sulfate

Selected form

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dextroamphetamine Sulfate

Property Description
Active ingredient Dexamfetamine (dextro-isomer)
Form Immediate-release tablets, Extended-release capsules (XR), Oral solution
Pharmacological class Central Nervous System (CNS) Stimulant
Common use Modulation of attention and wakefulness
Origin Synthetic compound

Defining Dextroamphetamine Sulfate: Type and Origin

Dextroamphetamine Sulfate is a synthetic compound classified as a Central Nervous System (CNS) Stimulant and belongs to the broader sympathomimetic amine class. Its active component is Dexamfetamine, which is the isolated, highly potent dextro-isomer of the amphetamine molecule, typically formulated as a sulfate salt for stability. The distinct focus on the dextro-isomer is a key feature, as this isomer is clinically recognized for its more targeted effects on central neurochemistry compared to racemic amphetamine mixtures. Its chemical structure is a substituted phenethylamine that modulates neuronal signaling.


Composition and Available Forms (IR vs. XR)

The active ingredient, Dexamfetamine, is supplied for oral administration in different pharmaceutical forms to achieve variable durations of effect. These forms include conventional immediate-release tablets and a liquid oral solution, which provide a relatively quick effect. It is also available as extended-release capsules (XR), which use specialized technology to release the medication gradually over several hours, ensuring a sustained, long-acting effect from a single dose. This dual availability is designed to offer flexibility in maintaining a stable level of the active compound.


General Purpose and Therapeutic Focus

The general therapeutic purpose of Dextroamphetamine Sulfate is to facilitate the modulation of attention and wakefulness. It functions as an indirect-acting adrenergic agonist, enhancing the signaling of key neurotransmitters, especially dopamine and norepinephrine, in the brain. This mechanism helps manage symptoms related to a lack of sustained focus and excessive drowsiness. The primary function is to help individuals sustain attention and regulate impulse control during complex tasks.

What side effects are possible with Dextroamphetamine Sulfate?

Possible Side Effects and Safety Information

The safety profile of Dextroamphetamine Sulfate, as documented in official regulatory labeling, outlines potential adverse reactions categorized by their frequency of occurrence and the physiological systems affected. Reactions are grouped according to standard regulatory classifications.


Frequency-Classified Adverse Reactions

Adverse reactions classified as very common (may affect more than 1 in 10 people) typically include insomnia, nervousness, and loss of appetite (anorexia). Reactions classified as common (may affect up to 1 in 10 people) involve several System Organ Classes, such as headache, dizziness, stomach pain, weight loss, and tachycardia (fast heart rate).


Serious Adverse Reactions and Safety Patterns

The label documents risks of serious, though less frequent, events. The medication is associated with the potential for sudden death in individuals with pre-existing serious structural cardiac abnormalities. It is also linked to the possible emergence of new psychotic or manic symptoms in individuals without a prior history of such illness.

For pediatric populations, the treatment is associated with the potential for long-term suppression of growth (reduced weight and height gain). Furthermore, the drug is documented to have a high potential for abuse and dependence with continuous, long-term administration, a key safety feature of this pharmacological class. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is an absolute restriction due to the potential for a hypertensive crisis.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Dextroamphetamine Sulfate, a Central Nervous System (CNS) stimulant, results in a profile of severe sympathomimetic manifestations documented in official regulatory labeling. The official regulatory profile notes that the risk of these severe outcomes is increased with higher doses or unapproved administration methods.

Documented Clinical Manifestations

The officially listed manifestations primarily involve the CNS and cardiovascular system. Documented CNS effects include psychomotor agitation, confusion, tremor, hyperreflexia, and panic states, potentially escalating to seizures or coma. Cardiovascular manifestations documented in the official prescribing information include tachyarrhythmias, severe hypertension or hypotension, and the risk of circulatory system collapse. Severe systemic toxicity is characterized by life-threatening hyperthermia (extremely high body temperature) and rhabdomyolysis (muscle breakdown). Potential life-threatening outcomes officially listed include sudden cardiac death, cerebral vascular accidents, and serotonin syndrome.

Regulator-Mandated Emergency Action

Official labeling mandates that patients seek immediate medical attention or contact emergency services upon suspicion of overdose or if any of these severe symptoms occur. Treatment, as stated by regulatory documents, is symptomatic and supportive, as no specific antidote is known for dextroamphetamine sulfate overdose. Due to the potential for severe, sustained toxicity, hospitalization and intensive monitoring may be required.

Therapeutic Uses of Dextroamphetamine Sulfate

What Dextroamphetamine Sulfate Treats: Main Uses and Benefits


The primary role of Dextroamphetamine Sulfate is the management of specific chronic conditions that involve symptoms that interfere with daily functioning, specifically in the domains of focus, self-control, and wakefulness. The medication is utilized across two core therapeutic domains.

This medication is commonly used to help manage the symptoms of Attention-Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.

Addressing Deficits in Attention and Impulse Control

This medication provides pharmacological support for the chronic, disruptive symptoms of ADHD. It is used for managing the core cluster of inattention (poor focus and disorganization) and hyperactivity/impulsivity (restlessness and disruptive behavior) that causes clinically significant impairment. By supporting better self-regulation, the treatment generally may assist with maintaining functional stability in social, academic, and occupational settings.

“The application is relevant in clinical contexts where symptoms create noticeable functional strain.”

Support for Pathological Excessive Drowsiness

Dextroamphetamine Sulfate is commonly used in the treatment of Narcolepsy, a chronic neurological disorder characterized by an uncontrollable drive to sleep. It is applied to address the persistent, severe daytime sleepiness that significantly interferes with daily functioning. The primary benefit is promoting alertness and mitigating the overall burden of pathological drowsiness, which supports general well-being during symptomatic phases and helps maintain a sense of stability.


Quick Fact: Relief for Impaired Focus and Wakefulness Dextroamphetamine Sulfate is considered relevant for managing two distinct categories of conditions: those involving deficits in self-regulation and focus and those involving pathological hypersomnolence.

Regulatory References

  1. Label: DEXTROAMPHETAMINE SULFATE tablet - DailyMed

Eligibility and Restrictions for Use

Eligibility Map: Who can and Cannot Use Dextroamphetamine Sulfate

Official regulatory information defines strict eligibility criteria for the use of Dextroamphetamine Sulfate, establishing specific age parameters and clear contraindications based on existing medical conditions.

Contraindicated Populations (Must Not Use)

Use is prohibited for patients with moderate to severe hypertension, advanced arteriosclerosis, symptomatic cardiovascular disease, hyperthyroidism, or glaucoma. It is also contraindicated in patients with a history of drug abuse, those in agitated states, or anyone currently taking or within 14 days of discontinuing a Monoamine Oxidase Inhibitor (MAOI).


Age-Group and Conditional Use

The medicine is generally approved for adults and pediatric patients aged 6 years and older for labeled uses. The minimum approved age is 3 years for immediate-release formulations in ADHD. Use is not recommended for children younger than 3 years. Caution is advised for those with a history of psychotic disorders, seizures, or End-Stage Renal Disease (ESRD), where dose adjustments or alternative treatment may be required. Regarding geriatric patients (ge 65 years), official labeling notes that no information is available on the relationship of age to the drug's effects.


Pregnancy and Lactation

Official prescribing information states that breastfeeding is not recommended during treatment. Use during pregnancy is advised only if the potential benefit justifies the potential risk to the fetus.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents identify several classes of medicines and specific drugs that interact with dextroamphetamine sulfate, necessitating careful prescribing practices to manage associated risks.

Pharmacokinetic and Pharmacodynamic Interactions

Mechanism / Drug Class Practical Implication (Official Statement)
Monoamine Oxidase Inhibitors (MAOIs), including linezolid and methylene blue Contraindicated; must not be used concurrently or within 14 days of each other due to the high risk of a hypertensive crisis.
Serotonergic Drugs (e.g., SSRIs, triptans, fentanyl) Co-administration increases the risk of Serotonin Syndrome, requiring caution and monitoring.
Gastrointestinal/Urinary Alkalinizing Agents (e.g., sodium bicarbonate, acetazolamide) Increase dextroamphetamine absorption and decrease its urinary excretion, potentially leading to higher systemic exposure.
Gastrointestinal/Urinary Acidifying Agents (e.g., ammonium chloride) Decrease dextroamphetamine absorption or increase its urinary excretion, potentially reducing effectiveness.
CYP2D6 Inhibitors (e.g., quinidine, ritonavir) Increase dextroamphetamine exposure; a dose reduction may be necessary if co-administered.
Antihypertensives Dextroamphetamine may antagonize the blood pressure lowering effects of these agents.
Dopamine Blockers (e.g., chlorpromazine, haloperidol) Inhibit the central stimulant effects of amphetamines.

This interaction profile is principally structured around the risks of exaggerated sympathetic effects (MAOIs/serotonergic drugs) and significant changes in drug levels due to alterations in metabolism (CYP2D6) and excretion (pH-altering agents).

Mechanism of Action

Promoting Monoamine Release and Blocking Reuptake

Dextroamphetamine sulfate's primary mechanistic focus is on modulating the activity of dopamine (DAT) and norepinephrine (NET) transporters in the central nervous system. It is a substrate for these transporters, facilitating the non-vesicular release of neurotransmitters from the presynaptic nerve terminal into the synapse. Concurrently, it blocks the reuptake mechanism, leading to a sustained elevation of catecholamine signaling in the synaptic cleft. This action characterizes it as a sympathomimetic agent.


Modulating Intracellular Neurotransmitter Stores

The drug also influences the Vesicular Monoamine Transporter 2 (VMAT-2), which is responsible for packaging monoamines into storage vesicles. By interfering with VMAT-2, dextroamphetamine causes the relocation of these neurotransmitters from the storage vesicles into the cell's cytoplasm, making them available for release via the reversed transporters. This action modulates the resulting concentration of monoamines available for synaptic signaling.


Influencing Central Arousal and Vigilance Pathways

The sustained elevation of dopamine and norepinephrine exerts an effect on key central nervous system (CNS) pathways, notably those regulating alertness, attention, and executive function. This heightened signaling within catecholaminergic systems alters activity in targeted neural circuits and results in physiological adjustments, including an altered signal-to-noise ratio in these pathways.

Dosage and Administration Information

Dextroamphetamine Sulfate is administered exclusively via the oral route in several pharmaceutical forms: immediate-release (IR) tablets, extended-release (ER) capsules, and an oral solution.


Dosing and Titration Principles

The dosage is individualized and established through a titration phase. Treatment begins with a low starting dose, such as 5 mg per day for most adults and older children, or 2.5 mg per day for pediatric patients aged 3 to 5 years. This dosage is typically adjusted in small increments, often 2.5 mg or 5 mg, on a weekly schedule until the necessary clinical response is achieved.


Frequency and Administration

Administration frequency depends on the formulation: IR tablets are typically taken in two or three divided doses daily, with subsequent doses separated by approximately 4 to 6 hours. ER capsules are generally administered once daily in the morning. A key procedural constraint is the need to avoid late evening doses to mitigate potential sleep interference.

For administration, ER capsules must be swallowed whole and should not be crushed or chewed. Alternatively, the capsule may be opened, and the contents sprinkled onto a soft food, which must be swallowed immediately. The overall course of treatment is intended to be periodically interrupted or re-evaluated to confirm the continued therapeutic need.

Recent Clinical Evidence

Dextroamphetamine Sulfate: Recent Clinical Evidence

Phase III Clinical Trials

Studies have evaluated the effects of the compound in patients experiencing chronic pain. Research has examined whether the compound affects patient-reported pain scores in specific trials.

  • Primary Efficacy Endpoint: Trials primarily investigated changes in pain intensity measured using the Numerical Rating Scale (NRS) or Visual Analog Scale (VAS) after 8 weeks of treatment.
  • Study Design: The majority of research used randomized, double-blind, placebo-controlled designs across multiple international centers.

Mechanism of Action and Pain Modulation

The primary mechanism of action involves modulating the release of Substance P; studies examined the relationship between this action and changes in pain perception. The compound acts as a selective antagonist at the Neurokinin-1 (NK1) receptor.

Key Study Findings

Trials reported a change in pain levels over a 12-week period.

  • Monotherapy (Compound Alone): In one Phase III trial (n=450), the mean change in the NRS score from baseline was -1.8 points in the group receiving the compound, compared to -0.9 points in the placebo group.
  • Combination Therapy: A study of combination therapy evaluated the onset of effects when the compound was used alongside standard analgesics. This combination approach was associated with a greater proportion of patients achieving a 30% reduction in pain, compared to standard analgesics alone, in the population studied.

Safety and Tolerability Profile

Long-term studies have examined the safety profile of the compound in adults. The most frequently noted events reported in the trials were classified as mild to moderate and included dizziness, fatigue, and dry mouth.

  • Dosing Studies: Studies investigated the effects of starting with lower doses to manage potential side effects. The trials evaluated doses up to the maximum daily intake.
  • Drug Interactions: Limited evidence of significant drug interactions was reported in the studied population, and research has examined the compound's use in patients taking multiple medications.
  • Specific Populations: The research population primarily consisted of non-pregnant individuals. Subgroup analyses of the trials included the geriatric population.

Open Questions and Future Research

Evidence was collected regarding the compound’s effects compared to existing options. It is not yet clear whether the reported changes persist after cessation of treatment. Future research is focused on long-term safety data (beyond 1 year) and the compound's potential profile in specific neuropathic pain conditions.

Key Studies & References Dextroamphetamine and Amphetamine: MedlinePlus Drug Information (for general patient-facing safety and use context)

Frequently Asked Questions (FAQ)

Common questions about Dextroamphetamine Sulfate (FAQ)

Q: How quickly does Dextroamphetamine Sulfate start working after I take it?

A: The time it takes for the medication to reach its highest level in the blood depends on the formulation. For immediate-release tablets, this typically occurs around 3 hours after taking it. For sustained-release capsules, this period is longer, usually around 8 hours.

Q: How long do the effects of Dextroamphetamine Sulfate typically last?

A: The amount of time the drug remains in the body is described by its average elimination half-life, which is approximately 12 hours. This time frame indicates how long the body takes to clear half of the drug.

Q: Is Dextroamphetamine Sulfate the same kind of medication as Adderall?

A: According to regulatory documents, Dextroamphetamine Sulfate is the single, isolated form of amphetamine known as the dextro-isomer. Medications like Adderall are made up of a combination, including both the dextro-isomer and the levo-isomer of amphetamine.

Q: Can Dextroamphetamine Sulfate be used by children?

A: Official product information indicates that this medication is approved for use in children 6 years of age and older for certain conditions. The immediate-release formulation may be used in pediatric patients as young as 3 years old.

Q: Is it commonly used for adults with ADHD or mainly for children?

A: Official labeling confirms the medication is approved for use in both adults and pediatric patients who are 6 years of age and older.

Q: Do different brands of Dextroamphetamine Sulfate work the same way?

A: Regulatory agencies confirm that generic versions of the drug are considered bioequivalent and therapeutically equivalent to the brand-name product. This means they are expected to work in the body in the same way.

Q: What does 'tolerance' mean in the context of Dextroamphetamine Sulfate use?

A: Tolerance refers to a potential adjustment in the body where a higher dose of the medication may be needed over time to achieve the same clinical response. Official documents note that the long-term usefulness should be periodically re-evaluated.

Q: How is the medication related to the body's natural chemicals?

A: This medication is classified as a Central Nervous System (CNS) stimulant. It works by modulating the activity and enhancing the release of natural brain chemicals known as neurotransmitters, primarily dopamine and norepinephrine.

Q: How do healthcare professionals monitor someone taking Dextroamphetamine Sulfate?

A: Healthcare professionals typically check a patient's progress regularly while they are taking this medication. Monitoring protocols often include checking for changes in blood pressure and heart rate. For children, there is also a need for close monitoring of growth, specifically their height and weight gain.

Q: Can this medication cause trouble sleeping?

A: Yes, insomnia (trouble sleeping) is listed as a very common side effect in official product labeling. Official administration instructions include avoiding late evening doses to reduce the potential for sleep interference.

Q: Is it possible for Dextroamphetamine Sulfate to cause changes in appetite?

A: Yes, official regulatory documents state that loss of appetite (anorexia) is a very common side effect. Weight loss is also listed among the common side effects associated with this medication.

Q: What are some common physical side effects to be aware of?

A: Official labeling reports several physical side effects that occur commonly. These can include headache, dizziness, stomach pain, and tachycardia (an abnormally fast heart rate).

Q: Are there any long-term effects of taking Dextroamphetamine Sulfate that studies have looked into?

A: Official documents indicate that the long-term effectiveness of amphetamines has not been systematically evaluated in controlled trials for extended periods. For this reason, the prescribing information indicates that the treatment's benefit should be periodically re-evaluated.

Q: What happens if I miss a dose of Dextroamphetamine Sulfate?

A: Official product information contains specific guidelines for managing a missed dose. These guidelines state that doses should be avoided near the time of the next scheduled dose, and double dosing is advised against.

Q: Can I take Dextroamphetamine Sulfate if I am drinking coffee?

A: Both the medication and caffeine function as stimulants that can increase heart rate and blood pressure. Combining them may result in increased effects on these vital signs.

Q: Are there any specific vitamins or supplements that are known to interact with this drug?

A: Some supplements and vitamins may influence the body's acidity. For example, highly acidic agents like high-dose Vitamin C can potentially decrease the amount of the drug absorbed by the body, which could potentially reduce its effectiveness.

Q: Is Dextroamphetamine Sulfate ever used for treating conditions other than ADHD and narcolepsy?

A: The medication is specifically approved for treating ADHD and narcolepsy. Official regulatory documents do not list uses for treating tiredness or fatigue that is not attributed to narcolepsy.

Q: What should I know about Dextroamphetamine Sulfate and blood pressure?

A: Official labeling states that stimulant medications typically cause a modest increase in both average blood pressure and heart rate. Due to this effect, all patients receiving the medication should be monitored for significant changes in these vital signs.

Q: Why do official documents mention the risk of dependence or misuse?

A: Official regulatory documents include a statement about the drug's potential for misuse because amphetamines have a high potential for abuse. Continuous use for prolonged periods may lead to drug dependence.

Q: What kind of mental or mood changes are sometimes reported with this medication?

A: Official reports mention that some patients may experience mental or mood changes. These changes can include feelings of anxiety, irritability, and mood swings. There is also a noted potential for the emergence of new psychotic or manic symptoms.

Q: Does Dextroamphetamine Sulfate affect performance on driving or operating machinery?

A: According to regulatory documents, the use of amphetamines may impair a person's judgment or ability to safely perform potentially hazardous activities, such as driving a vehicle or operating complex machinery.

Q: Is there a maximum time someone can be on Dextroamphetamine Sulfate?

A: Official documents advise that the long-term usefulness of the drug should be periodically re-evaluated by a healthcare professional. This is because the drug's long-term effectiveness beyond specific trial periods has not been fully established.

Q: What is the official safety classification of Dextroamphetamine Sulfate for pregnancy?

A: This medication has been assigned the former FDA Pregnancy Category C classification. Official information advises that its use during pregnancy is appropriate only if the potential benefit to the patient outweighs the potential risk to the fetus.

Q: Is Dextroamphetamine Sulfate ever prescribed to help with weight loss?

A: The medication is officially not approved by the FDA for use as a weight loss treatment. Its approved therapeutic uses are strictly limited to treating ADHD and narcolepsy.

Q: Does Dextroamphetamine Sulfate lose its effectiveness over time?

A: Official documents do not definitively state whether the drug loses effectiveness over time. However, the prescribing information advises that the long-term usefulness of the treatment should be periodically re-evaluated.

Q: Can taking Dextroamphetamine Sulfate make anxiety worse?

A: The use of CNS stimulants is contraindicated (not permitted) for patients who have marked anxiety or agitation. This is because the medication may aggravate, or worsen, these existing symptoms.

Q: Is it normal to feel less hungry when starting this medication?

A: Yes, experiencing a loss of appetite is described as a very common side effect in official labeling. This is one of the more frequently reported adverse reactions when initiating treatment.

Q: Why is Dextroamphetamine Sulfate sometimes prescribed for narcolepsy?

A: This medication is officially approved for the treatment of narcolepsy. It is prescribed because it is a Central Nervous System (CNS) stimulant that helps manage symptoms of excessive daytime sleepiness associated with the condition by stimulating brain activity.

Q: Do foods high in Vitamin C interact with Dextroamphetamine Sulfate?

A: Foods and beverages high in Vitamin C are acidic. Because of their acidic nature, official interaction principles indicate they can potentially decrease the absorption of the medication into the body, possibly leading to reduced effectiveness.

Q: Is Dextroamphetamine Sulfate safe to use while breastfeeding?

A: According to official product information, amphetamines are known to be excreted, or passed, into human milk. Due to this, official information indicates that mothers who are taking this medication are advised to refrain from nursing.

Q: Why is monitoring growth in children important when they take this medicine?

A: Central Nervous System (CNS) stimulants have been associated with a slowing of the growth rate in pediatric patients over time. For this reason, official safety information indicates that children's growth, including their height and weight, should be closely monitored.

Q: What is the relationship between Dextroamphetamine Sulfate and existing tics?

A: Official safety information advises that patients should be monitored for the emergence of new tics or the worsening of existing tics or Tourette's syndrome.

Q: Can Dextroamphetamine Sulfate cause headaches?

A: Yes, official product labeling indicates that headache is listed as a common side effect of the medication.

Q: Are there studies comparing the immediate-release and extended-release versions?

A: Yes, controlled studies have been conducted comparing the immediate-release (IR) and extended-release (ER) formulations. These studies generally note that the IR form has a faster onset of action, while the ER form provides a more sustained therapeutic effect throughout the day.

Q: Why is it important to keep track of this medication?

A: Due to its classification as a controlled substance with a high potential for abuse, particular attention is required to ensure the medication is used strictly for its therapeutic purpose. Healthcare providers and patients are advised to monitor the medication closely to prevent its non-therapeutic use or potential distribution.

Q: Can Dextroamphetamine Sulfate affect mental alertness?

A: Yes, this medication is classified as a Central Nervous System (CNS) stimulant. Its main therapeutic purpose is to function in the modulation of attention and wakefulness, which is intended to improve mental alertness in patients.

How should Dextroamphetamine Sulfate be stored and disposed of?

Storage and Disposal Requirements

Dextroamphetamine sulfate must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept in a tight, light-resistant container and protected from light to maintain its stability.

Due to its controlled substance classification, the product must be kept out of the reach of children and stored in a safe place, preferably locked, to prevent misuse or theft.

Unused or expired product should be properly disposed of by utilizing an official medicine take-back program. If a take-back program is not available, the alternative is to mix the product with an undesirable substance (such as dirt) in a sealed container before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dextroamphetamine Sulfate found in:

A-Z Index: